Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Retrieved on:
Friday, March 15, 2024
Research, Mental Health, FDA, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, GAD, Selective serotonin reuptake inhibitor, Breakthrough therapy, Inc., Patient, Disease, Human, Anxiety, DMT, Epidemiology, Psychiatry, Anxiety disorder, Safety, E36, Food, Pharmaceutical industry
“Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.
Key Points:
- “Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.
- The CYB004-002 Phase 2 study is a randomized, double-blind study which will evaluate the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed.
- The study will enroll participants with moderate to severe GAD and a score of ≥10 on the GAD-7 anxiety scale.
- Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019.